Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corp (DXR) delivers critical advancements in blood volume measurement through its FDA-cleared BVA-100 technology. This page provides investors and healthcare professionals with centralized access to official news, financial updates, and clinical developments related to DXR’s diagnostic innovations.
Track press releases covering product milestones, peer-reviewed research validations, and strategic partnerships. Stay informed about quarterly earnings, regulatory filings, and advancements in fluid management diagnostics. All content is sourced directly from verified company communications to ensure accuracy.
Key updates include BVA-100 adoption metrics, clinical trial outcomes, and operational expansions. Bookmark this page for real-time insights into DXR’s role in transforming patient diagnostics through precise blood volume analysis. Regularly updated to serve as your primary resource for unbiased, factual Daxor Corp developments.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has been awarded a $550K matching-fund extension from the U.S. Defense Health Agency (DHA) to its Phase II SBIR contract. This funding will support the integration of hematocrit measurement into a future generation Blood Volume Analyzer (BVA).
The upgrade aims to streamline the BVA test by eliminating the need for third-party hematocrit testing devices. This marks Daxor's eighth SBIR award, demonstrating the DHA's ongoing commitment to advancing next-generation medical technologies. The company's goal is to make blood volume measurement faster and easier in various settings, from bedside to clinical testing labs and combat zones.
Daxor (Nasdaq: DXR) announced the expansion of its blood volume analysis (BVA) technology, including the launch of new BVA programs and the increased adoption of its ezBVA Lab service. This CLIA-certified facility provides next-day blood volume analysis results on-demand. Recent expansions include a regional referral center for Northeast Arkansas and Southeast Missouri, a 300-bed Covenant Health affiliate, and a leading South Texas teaching hospital and Level 1 trauma center. CEO Michael Feldschuh highlighted that strategic investments in sales and marketing are driving growth, with further developments expected in the year's second half.
Daxor (Nasdaq: DXR) will exhibit at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting from June 20-22, 2024, at the Rosen Shingle Creek Resort in Orlando, Florida. The company will showcase its BVA-100™ Guided-Care technology, which provides precise blood volume analysis to improve heart failure management. Daxor claims that this technology can reduce hospital stays, 30-day readmissions, and mortality rates, potentially transforming cardiovascular care. The event offers a platform for Daxor to present evidence supporting these benefits.
Daxor (Nasdaq: DXR) has appointed Dr. John L. Jefferies as Chief Medical Officer. Dr. Jefferies, an esteemed cardiologist with extensive clinical and commercial experience, will guide Daxor's strategic and clinical affairs. His role aims to accelerate the adoption of Daxor's diagnostic solutions in clinical practice, driving growth and collaboration with healthcare professionals. Dr. Jefferies brings a robust background in heart failure, cardiomyopathies, genetics, and AI, having published over 300 peer-reviewed manuscripts and served in numerous academic and leadership roles.
FAQ
What is the current stock price of DAXOR (DXR)?
What is the market cap of DAXOR (DXR)?
